Cutting-edge therapies and niche biomedical topics to be the focus of BioBusiness Asia 2017, 28-29 June
BioTaiwan 2017, the annual biotech-themed convention, will take place June 28 to July 2 in Taipei, Taiwan.
Kicking off the week-long calendar of events will be the two-day BioBusiness Asia (BBA) Conference, one of Asia’s leading annual business-focused biotech gatherings. The focus of BBA this year, as in other recent years, will be on identifying future technological trends, examining regional niches, and exploring new business models and opportunities.
An impressive lineup of international speakers promises to delve deep into some of the most cutting-edge topics of the day, including precision medicine, immuno-oncology, next-generation sequencing, stem and cell therapy, synthetic biology, microbiome and AI, big data-driven mobile healthcare.
Select Speaker introductions
Patrick Flochel, lead author of Ernst & Young’s widely anticipated 28th annual global biotechnology report ‘Beyond Borders will lead the Plenary Session on the first day of BBA with a talk entitled ‘Biotechnology Financing and Deal-Making State of the Industry.’
With qualifications in engineering, computer science and medicine, Timothy Lu has a unique understanding of how and where technologies can come together to form new opportunities. Starting up a number of companies and with a particular interest in synthetic biology, Lu was selected by MIT Technology Review as one of its ‘Top Innovators under 35’ in 2010. Lu will talk about next-generation therapeutic platforms at BBA.
Jin-Long Chen, founder of San Francisco-based NGM Biopharmaceuticals was recently profiled as a possible ‘next Genentech’ by BioSpace. Chen’s presentation will focus on how to build a company optimized to discover new drugs.
Allen Chao, founding chairman of Watson Pharmaceuticals, now Actavis, and currently the world’s third-largest generics drug companies, is one of Taiwan’s most successful bioindustry representatives. He also served as the president of US-Taiwan biosimilars developer Tanvex BioPharma since 2008. In his talk among other topics, Chao will recall his journey from generic pharmaceuticals to the world of biologics.
Yuh-geng Tsay, currently with VIVO Capital, was previously Group President of Thermo Fisher’s Specialty Diagnostic business through a number of mergers and acquisitions. Tsay will talk about building a successful global medical device business.
Larry Hsu, chairman of Lifemax Healthcare International Corporation, and founder of Impax Pharmaceuticals, now Impax Laboratories, will be giving a presentation on Taiwan’s current standing and future potential in the niche fields of drug repurposing and new drug delivery technologies.
BioTaiwan 2017 Events
BBA is only a part of BioTaiwan 2017 that also includes the BioTaiwan Exhibition, company presentation, one-on-one partnering and a wide range of seminars and workshops. And in a change from previous years, the ‘Greater China Opportunities’ conference is now the ‘Greater China and Asia-Pacific Opportunities’ conference, to be held on June 30 to match government’s recent ‘Southbound’ industrial policy. The format will remain the same, identifying opportunities, partnering models and success stories between companies from Taiwan, mainland China and now including SE Asia.
About Taiwan Bio Industry Organization
Taiwan Bio Industry Organization (TBIO) established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. We are a strong arm to foster the development of biotechnology in Taiwan. Our mission is to provide advocacy, business development, international partnership and communication service for our members.
Daisy Tsai / Tel : +886-2-26558692 / Email : email@example.com